Published recently in US Ophthalmic Review, the peer-reviewed journal from touchOPHTHALMOLOGY, Sameh Mosaed discusses the COMPASS study - the largest randomized clinical trial to date on a minimally invasive glaucoma surgery device, the CyPass® Micro-Stent. The CyPass Micro-Stent was able to lower intraocular pressure (IOP) more than modern cataract surgery (phacoemulsification and intraocular lens implantation) alone, and should be considered for patients with mild to moderate glaucoma already scheduled to undergo phacoemulsification surgery. The two-year outcomes of the COMPASS study found mean IOP reductions of 7.4 mmHg in the CyPass Micro-Stent group and no vision-threatening adverse events; more than 98% of subjects in the CyPass Micro-Stent group achieved 20/40 or better best-corrected visual acuity.
The full peer-reviewed, open-access article is available here:
Disclosure:Sameh Mosaed is a speaker and consultant for Alcon Laboratories. The publication if this article was supported by Alcon Laboratories.
Note to the Editor
touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the US Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.